Prescription portability between countries posts 91–115
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
Collapsed as off-topic by two members at trust level 3 or above
Worth separating two things that post #94 runs together.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Coming back to post #98, because the follow-up matters more than the original answer.
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
Picking up post #98: that is the part I would want checked first.
Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
On post #100 — agreed on the reasoning, with one qualification.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
Collapsed as off-topic by two members at trust level 3 or above
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
post #106 is right about the mechanism and I think understates the practical bit.
Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.
Worth separating two things that post #104 runs together.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.
Coming back to post #108, because the follow-up matters more than the original answer.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
Collapsed as off-topic by two members at trust level 3 or above
post #111 answers the question as asked. The question underneath it is different.
Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
Worth separating two things that post #111 runs together.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
|
+124 | 132 | 9.2k | 2mo |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+6 | 10 | 41k | 11mo |
|
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 182 | 21h | |
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…
|
2 | 22k | 1h | |
|
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+6 | 11 | 240 | 22mo |
Related topics — sharing the tags personal import, MHRA, telehealth
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
|
2 | 5k | 11mo | |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 5.8k | 15mo | |
|
What changed in 2026, by region — does this still hold?
What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…
|
+20 | 25 | 50k | 1d |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+87 | 94 | 1.1k | 21d |